Literature DB >> 15777350

Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3.

Ersi Voskaridou, Evangelos Terpos.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15777350     DOI: 10.1111/j.1600-0609.2004.00395.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  4 in total

1.  Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Charoula Xirakia; Konstantinos Varvagiannis; Georgios Boutsikas; Antonios Bilalis; Efstathios Kastritis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

2.  Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels.

Authors:  Francesca Rossi; Silverio Perrotta; Giulia Bellini; Livio Luongo; Chiara Tortora; Dario Siniscalco; Matteo Francese; Marco Torella; Bruno Nobili; Vincenzo Di Marzo; Sabatino Maione
Journal:  Haematologica       Date:  2014-09-12       Impact factor: 9.941

3.  Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.

Authors:  Ersi Voskaridou; Ioannis Ntanasis-Stathopoulos; Athanasios Papaefstathiou; Dimitrios Christoulas; Maria Dimopoulou; Konstantina Repa; Athanasios Papatheodorou; Melpomeni Peppa; Evangelos Terpos
Journal:  Blood Adv       Date:  2018-11-13

4.  Decreased Bone Formation Explains Osteoporosis in a Genetic Mouse Model of Hemochromatosiss.

Authors:  Mathilde Doyard; Daniel Chappard; Patricia Leroyer; Marie-Paule Roth; Olivier Loréal; Pascal Guggenbuhl
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.